CD47 and lymphoma: The preclinical data presented herein appears to support the contention that combinations of checkpoint targeted drugs, in this case the dual targeting of PD1 and CD47, may be associated with improved activity in models of lymphoma not historically recognized to be sensitive to PD1 or CD47 blockade.